Division of Transplant Surgery, University of Virginia, Charlottesville, VA, USA.
Am J Case Rep. 2021 May 6;22:e927532. doi: 10.12659/AJCR.927532.
BACKGROUND Kidneys from deceased donors who were positive for hepatitis C virus (HCV) on a nucleic acid amplification test (NAT) are not given to anti-HCV antibody-negative recipients. This is because of the high risk of HCV transmission, combined with the lack of effective antiviral treatment. Several studies have demonstrated rates of transmission of HCV from anti-HCV-positive/HCV NAT-positive donors to anti-HCV-negative recipients of 100%. Ours is the first report of transplantation of a kidney from an anti-HCV antibody-positive/HCV NAT-positive donor into an anti-HCV antibody-negative recipient who remains anti-HCV antibody-negative at 3 months after transplant with no treatment. CASE REPORT A 49-year-old man had a history of end-stage renal disease that was presumed to be secondary to type ll diabetes. He received a kidney from a deceased donor who was HCV antibody-positive/NAT-negative. The patient's HCV antibody status was checked prior to transplant and he was found to be negative and nonreactive. Since the transplant, his HCV viral load has been checked 5 times, on postoperative days 15, 23, 44, 62, and 64; each time, it has been undetectable. Furthermore, the patient's HCV antibody status was rechecked 1 month after transplant and it remained negative and nonreactive. CONCLUSIONS Further research is required on the accuracy of polymerase chain reaction as an indicator of donor HCV infection when the quantity of the viral load is not reported.
核酸扩增试验(NAT)检测到丙型肝炎病毒(HCV)阳性的已故供体的肾脏不会给予抗 HCV 抗体阴性的受者。这是因为 HCV 传播的风险很高,再加上缺乏有效的抗病毒治疗。几项研究表明,HCV 从抗 HCV 阳性/HCV NAT 阳性供体传播到抗 HCV 阴性受者的比率为 100%。我们的报告是首例将抗 HCV 抗体阳性/HCV NAT 阳性供体的肾脏移植到抗 HCV 抗体阴性受者体内的病例,该受者在移植后 3 个月未接受任何治疗,仍保持抗 HCV 抗体阴性。
一名 49 岁男性患有终末期肾病,据推测是由 2 型糖尿病引起的。他接受了一名 HCV 抗体阳性/NAT 阴性的已故供体的肾脏。患者在移植前检查了 HCV 抗体状况,结果为阴性且无反应。自移植以来,他的 HCV 病毒载量已被检查了 5 次,分别在术后第 15、23、44、62 和 64 天;每次检测均为未检测到。此外,患者在移植后 1 个月再次检查 HCV 抗体状态,结果仍为阴性且无反应。
当未报告病毒载量时,需要进一步研究聚合酶链反应作为供体 HCV 感染指标的准确性。